25

CLAIMS PVS

- 1. A pharmaceutical composition for parenteral administration, which comprises a peptide and dimethyl sulfone.
- 5 2. A pharmaceutical composition according to claim 1, wherein the amount of dimethyl sulfone is of from 40 to 400 mM.
 - 3. A pharmaceutical composition according to claim 2, wherein amount of dimethyl sulfone is of from 125 to 350 mM.
 - 4. A pharmaceutical composition according to any one of the claims 1 to 3, wherein the composition is a solution.
- 5. A pharmaceutical composition according to any one of the claims 1 to 3, wherein the composition is a suspension.
 - 6. A pharmaceutical composition according to any one of the preceding claims, which is suitable for administration by injection or infusion.
- 7. A pharmaceutical composition according to claim 6, which is suitable for subcutaneous administration.
 - 8. A pharmaceutical composition according to claim 6, which is suitable for intramuscular administration.
 - A pharmaceutical composition according to claim 6, which is suitable for intravenous administration.
- 10. A pharmaceutical composition according to any one of the preceding claims 1 to 5, which30 is suitable for pulmonal administration.
 - 11. A pharmaceutical composition according to any one of the preceding claims 1 to 5, which is suitable for ophthalmic administration or topical administration.

20

- 12. A pharmaceutical composition according to any one of the preceding claims, wherein the peptide is human growth hormone, GLP-1, GLP-2, insulin, Factor VII, Factor VIII, erythropoeitin (EPO), glucagon, interleukin, such as interleukin-2 (IL-2), interferon-α or interferon-β, or an analogue thereof, or a derivative of any such peptide or analogue.
- 13. A pharmaceutical composition according to claim 12, wherein the peptide is human insulin or an analogue thereof, or a derivative of human insulin or the human insulin analogue.
- 14. A pharmaceutical composition according to claim 13, wherein the peptide is human insu-10 lin.
 - 15. A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.
- 15 16. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.
 - 17. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.
 - 18. A pharmaceutical composition according to claim 13, wherein the peptide is $N^{\epsilon B29}$ -tetradecanoyl des (B30)-human insulin.
- 19. A pharmaceutical composition according to claim 13, wherein the peptide is
 Gly(A21) Arg(B31) Arg(B32)-human insulin.
 - 20. A pharmaceutical composition according to claim 13, wherein the peptide is N^{εB29}–lito-choloyl-γ-glutamyl des (B30)-human insulin.
- 30 21. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(8)human GLP-1.
 - 22. A pharmaceutical composition according to claim 12, wherein the peptide is Arg(34), N- ϵ -(γ -Glu(N- α -hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

- 23. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(2)-human GLP-2.
- 24. Use of dimethyl sulfone as an isotonicity agent in a pharmaceutical composition for parenteral administration.
 - 25. Use of dimethyl sulfone as an isotonicity agent in a pharmaceutical composition for parenteral administration comprising a peptide.
- 26. Use according to claims 24 or 25, wherein the amount of dimethyl sulfone in the pharmaceutical composition is of from 40 to 400 mM.
 - 27. Use according to claim 26, wherein the amount of dimethyl sulfone in the pharmaceutical composition is of from 125 to 350 mM.
 - 28. Use according to any one of the claims 24 to 27, wherein the composition is a solution.
 - 29. Use according to any one of the claims 24 to 27, wherein the composition is a suspension.
- 30. Use according to any one of the claims 24 to 29, wherein the composition is suitable for administration by injection or infusion.
- 31. Use according to claim 30, wherein the composition is suitable for subcutaneous admini-25 stration.
 - 32. Use according to claim 30, wherein the composition is suitable for intramuscular administration.
- 30 33. Use according to claim 30, wherein the composition is suitable for intravenous administration.
 - 34. Use according to any one of the claims 24 to 29, wherein the composition is suitable for pulmonal administration.

25

30

- 35. Use according to any one of the claims 24 to 29, wherein the composition is suitable for ophthalmic administration or topical administration.
- 36. Use according to any one of the preceding claims 24 to 35, wherein the peptide is human growth hormone, GLP-1, GLP-2, insulin, Factor VII, Factor VIII, erythropoeitin (EPO), glucagon, interleukin, such as interleukin-2 (IL-2), interferon-α or interferon-β, or an analogue thereof, or a derivative of any such peptide or analogue.
- 37. Use according to claim 36, wherein the peptide is human insulin or an analogue thereof, 10 or a derivative of human insulin or the human insulin analogue.
 - 38. Use according to claim 37, wherein the peptide is human insulin.
 - 39. Use according to claim 37, wherein the peptide is Asp(B28)-human insulin.
 - 40. Use according to claim 37, wherein the peptide is Lys(B28) Pro(B29)-human insulin.
 - 41. Use according to claim 37, wherein the peptide is Lys(B3) Glu(B29)-human insulin.
- 42. Use according to claim 37, wherein the peptide is N^{ε829}-tetradecanoyl des (B30)-human insulin.
 - 43. Use according to claim 37, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.
 - 44. Use according to claim 37, wherein the peptide is $N^{\epsilon B29}$ —litocholoyl- γ -glutamyl des (B30)-human insulin.
 - 45. Use according to claim 36, wherein the peptide is Gly(8)-human GLP-1.
 - 46. Use according to claim 36, wherein the peptide is Arg(34), N- ϵ -(γ -Glu(N- α -hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.
 - 47. Use according to claim 36, wherein the peptide is Gly(2)-human GLP-2.